Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tam

Showing results (871-880 of 922) with videos related to

Pageof 93
Sort By:
Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.
Human Molecular Genetics|August 13, 2013
Genome-wide association study identifies ZFHX1B as a susceptibility locus for severe myopiaChiea Chuen Khor, Masahiro Miyake, Li Jia Chen, et al.
Nature Genetics|September 1, 2014
Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucomaYuhong Chen, Ying Lin, Eranga N Vithana, et al.
Vaccine|December 17, 2009
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young childrenLucy Chai See Lum, Charissa Fay Borja-Tabora, Robert F Breiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Pageof 93

Showing results (871-880 of 922) with videos related to

Sort By:
Pageof 93
Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.
Human Molecular Genetics|August 13, 2013
Genome-wide association study identifies ZFHX1B as a susceptibility locus for severe myopiaChiea Chuen Khor, Masahiro Miyake, Li Jia Chen, et al.
Nature Genetics|September 1, 2014
Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucomaYuhong Chen, Ying Lin, Eranga N Vithana, et al.
Vaccine|December 17, 2009
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young childrenLucy Chai See Lum, Charissa Fay Borja-Tabora, Robert F Breiman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patientsChristian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Leukemia|June 9, 2017
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLJ R Brown, P Hillmen, S O'Brien, et al.
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
Pageof 93